- Home
- BTAI vs TSBX Comparison
BTAI vs TSBX Comparison
Compare BTAI & TSBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- TSBX
- Stock Information
- Founded
- BTAI 2017
- TSBX 2015
- Country
- BTAI United States
- TSBX United States
- Employees
- BTAI N/A
- TSBX N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- TSBX
- Sector
- BTAI Health Care
- TSBX
- Exchange
- BTAI Nasdaq
- TSBX Nasdaq
- Market Cap
- BTAI 8.3M
- TSBX 7.7M
- IPO Year
- BTAI 2018
- TSBX 2023
- Fundamental
- Price
- BTAI $1.93
- TSBX $0.36
- Analyst Decision
- BTAI Buy
- TSBX Buy
- Analyst Count
- BTAI 5
- TSBX 3
- Target Price
- BTAI $34.60
- TSBX $4.75
- AVG Volume (30 Days)
- BTAI 289.2K
- TSBX 479.7K
- Earning Date
- BTAI 08-05-2025
- TSBX 08-13-2025
- Dividend Yield
- BTAI N/A
- TSBX N/A
- EPS Growth
- BTAI N/A
- TSBX N/A
- EPS
- BTAI N/A
- TSBX N/A
- Revenue
- BTAI $1,852,000.00
- TSBX N/A
- Revenue This Year
- BTAI $5.03
- TSBX N/A
- Revenue Next Year
- BTAI $291.01
- TSBX N/A
- P/E Ratio
- BTAI N/A
- TSBX N/A
- Revenue Growth
- BTAI 5.47
- TSBX N/A
- 52 Week Low
- BTAI $1.17
- TSBX $0.29
- 52 Week High
- BTAI $21.92
- TSBX $2.69
- Technical
- Relative Strength Index (RSI)
- BTAI 56.97
- TSBX 52.27
- Support Level
- BTAI $1.69
- TSBX $0.33
- Resistance Level
- BTAI $2.08
- TSBX $0.37
- Average True Range (ATR)
- BTAI 0.20
- TSBX 0.03
- MACD
- BTAI 0.02
- TSBX -0.00
- Stochastic Oscillator
- BTAI 61.84
- TSBX 53.00
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About TSBX Turnstone Biologics Corp.
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.